Stay updated on Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.

Latest updates to the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page
- Check6 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing the prior v3.4.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 added. The previous notice about a lapse in government funding and related operating status information (Revision: v3.4.1) was removed.SummaryDifference0.4%

- Check41 days agoChange DetectedA site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status was added. The revision tag changed from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check49 days agoChange DetectedAdded a 'Show glossary' option and updated footer labels to 'Last Update Submitted that Met QC Criteria' with a 'Revision: v3.4.0' note.SummaryDifference0.2%

- Check56 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4; no trial details or visible content were modified.SummaryDifference0.1%

- Check84 days agoChange DetectedA new Locations section is added with District of Columbia listed as a study location, replacing the prior District of Columbia Locations entry and removing the HHS Vulnerability Disclosure link.SummaryDifference0.2%

Stay in the know with updates to Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combining Pembrolizumab and PEG-Intron for Cholangiocarcinoma Clinical Trial page.